<DOC>
	<DOCNO>NCT02133690</DOCNO>
	<brief_summary>This Phase 3 multicentre , randomize , double blind , placebo-controlled study determine effectiveness rotavirus vaccine .</brief_summary>
	<brief_title>A Clinical Trial Study Effect Safety Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis Healthy Indian Infants</brief_title>
	<detailed_description>The hypothesis three dose series BRV-PV administer orally healthy Indian infant , initial dose give 6-8 week age follow vaccination monthly interval , significantly reduce incidence severe rotavirus gastroenteritis ( SRVGE ) . Duration follow-up age 2 year enrol child . The study power detect vaccine efficacy significantly great 10 % ( 95 % confidence interval lower bound &gt; 10 % ) true vaccine efficacy 50 % high .</detailed_description>
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infant establish medical history clinical examination enter study . Age : 68 week time enrollment . Parental ability willingness provide inform consent . Parent intend remain area child study period . Presence diarrhea vomit previous 72 hour day enrollment ( temporary exclusion ) Presence fever day enrollment ( temporary exclusion ) . Acute disease time enrollment ( temporary exclusion ) Concurrent participation another clinical trial throughout entire timeframe study . Presence significant malnutrition ( weightforheight zscore &lt; 3SD median ) systemic disorder ( cardiovascular , pulmonary , hepatic , renal , gastrointestinal , hematological , endocrine , immunological , dermatological , neurological , cancer autoimmune disease ) determine medical history and/or physical examination would compromise subject 's health likely result nonconformance protocol . History congenital abdominal disorder , intussusception abdominal surgery Known suspect impairment immunological function base medical history physical examination . Household contact immunosuppressed individual pregnant woman . Prior receipt rotavirus vaccine . A known sensitivity allergy component study vaccine . Major congenital genetic defect . History persistent diarrhea ( define diarrhea 14 day ) . Participant 's parent able , available willing accept active weekly followup study staff . Has receive immunoglobulin therapy and/or blood product since birth plan administration study period . History chronic administration ( defined 14 day ) immunosuppressant include corticosteroid . Infants inhale topical steroid may permit participate study . History neurologic disorder seizure . Any medical condition parents/infant , judgment investigator , would interfere serf contraindication protocol adherence participant 's parent ' ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>8 Weeks</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>rotavirus</keyword>
	<keyword>rotavirus vaccine</keyword>
	<keyword>BRV-PV</keyword>
</DOC>